Management of β-agonist overuse: Why and how?

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 4, 2008, Pages 836-838

  Taylor, D Robin ^a   Hannah, Debbie ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b DUNEDIN HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; FLUTICASONE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; OMEPRAZOLE; PREDNISONE; SALBUTAMOL; THEOPHYLLINE;

AGED; ANAMNESIS; ASTHMA; BRONCHOSPASM; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; HOSPITAL DISCHARGE; HUMAN; LETTER; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; THORAX RADIOGRAPHY; TREATMENT PLANNING; TREATMENT RESPONSE;

ADRENERGIC BETA-AGONISTS; AGED; ASTHMA; DYSPNEA; FEMALE; HUMANS;

EID: 53049089304     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.07.025     Document Type: Letter

References (11)

1. Giembycz M.A., Kaur M., Leigh R., and Newton R. A Holy Grail of asthma management: toward understanding how long-acting beta(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 153 (2008) 1090-1104
2. Agarwal S.K., and Marshall Jr. G.D. Beta-adrenergic modulation of human type-1/type-2 cytokine balance. J Allergy Clin Immunol 105 (2000) 91-98
3. Panina-Bordignon P., Mazzeo D., Lucia P.D., D'Ambrosio D., Lang R., Fabbri L., et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. J Clin Invest 100 (1997) 1513-1519
4. Lai C.K., Twentyman O.P., and Holgate S.T. The effect of an increase in inhaled allergen dose after rimiterol hydrobromide on the occurrence and magnitude of the late asthmatic response and the associated change in nonspecific bronchial responsiveness. Am Rev Respir Dis 140 (1989) 917-923
5. Aldridge R.E., Hancox R.J., Robin Taylor D., Cowan J.O., Winn M.C., Frampton C.M., et al. Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am J Respir Crit Care Med 161 (2000) 1459-1464
6. Lazarus S.C., Boushey H.A., Fahy J.V., Chinchilli V.M., Lemanske Jr. R.F., Sorkness C.A., et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 285 (2001) 2583-2593
7. Taylor D.R., Sears M.R., and Cockcroft D.W. The beta-agonist controversy. Med Clin North Am 80 (1996) 719-748
8. McGraw D.W., Almoosa K.F., Paul R.J., Kobilka B.K., and Liggett S.B. Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest 112 (2003) 619-626
9. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
10. Wenzel S., and Szefler S.J. Managing severe asthma. J Allergy Clin Immunol 117 (2006) 508-511
11. Tattersfield A.E., Lofdahl C.G., Postma D.S., Eivindson A., Schreurs A.G., Rasidakis A., et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 357 (2001) 257-261